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Original Paper
Differences in craving for cannabis between
schizophrenia patients using risperidone,
olanzapine or clozapine
Marise Machielsen1, Albertine Scheltema Beduin1, Nienke Dekker1
and Genetic Risk and Outcome of Psychosis (GROUP) investigators:
Rene´ S Kahn2, Don H Linszen1, Jim van Os3, Durk Wiersma4,
Richard Bruggeman4, Wiepke Cahn2, Lieuwe de Haan1,
Lydia Krabbendam3 and Inez Myin-Germeys3
Abstract
Substance abuse and psychotic disorders have a high rate of comorbidity. Both disorders are associated with changes in the dopaminergic transmission
in the mesocorticolimbic pathways of the brain. Since antipsychotic medications interact with the dopamine receptors in these pathways, these
medications could affect craving for substances. In the current study, the effect of clozapine (n¼ 27, mean dosage 350mg), risperidone (n¼ 54, mean
dosage 3.46mg) and olanzapine (n¼ 60, mean dosage 13.78mg) on subjective craving for cannabis was compared in 123 patients with cannabis
dependence and psychotic disorder. Patients treated with risperidone reported significantly more craving compared with patients treated with
clozapine (Z¼3.19, p¼ .001) or olanzapine (Z¼2.24, p¼ .025). No significant differences in craving between clozapine and olanzapine were
found. These results are in concordance with findings in the literature on this subject and could be explained by differences in three dopamine
mediated mechanisms of these compounds: 1) occupancy rate of dopamine D2 receptors, 2) dissociation rate of dopamine D2 receptors, 3) D1/D2
occupancy ratio. Risperidone and clozapine show a maximal difference in D2 receptor occupancy rate, dissociation rate and D1/D2 ratio. Olanzapine is
intermediate between risperidone and clozapine in these characteristics.
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Introduction
Substance abuse is a major problem in patients with psy-
chotic disorders (Dixon, 1999; Linszen et al., 1994; Regier
et al., 1990). Several theories have been proposed to explain
the association between substance abuse and psychosis
(Lubman et al., 2010). The ‘self-medication’ theory states
that patients use substances to relieve (pre-)psychotic symp-
toms or side eﬀects of antipsychotic medication (Khantzian,
1985). However, studies testing this theory have not been
conclusive so far (Potvin et al., 2006; Schaub et al., 2008).
The theory of ‘common causes’ proposes that the high co-
morbidity rate between psychotic disorders and substance
use disorders could be caused by common underlying bio-
logical, personality or environmental factors (Lubman
et al., 2010). Since substance abuse and psychotic disorders
are both associated with changes in the dopaminergic trans-
mission in the mesocorticolimbic pathways of the brain,
this could be one of the possible explanations for the
high comorbidity rate (Green, 2005). Antipsychotic medica-
tions inﬂuence the dopaminergic neurotransmission in these
pathways and could therefore inﬂuence the severity of
substance abuse in patients. Blum et al. (2000) described the
reward deﬁciency hypothesis in which they state that patients
with a relatively low level of dopaminergic transmission in the
mesocorticolimbic system are more vulnerable to substance
abuse. Substance use results in a strong increase in the release
of dopamine in the mesocorticolimbic system (Volkow et al.,
2004), which is associated with a feeling of pleasure/reward.
Chronic substance abuse, on the other hand, decreases the
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level of dopamine in the orbitofrontal cortex (Volkow and
Fowler, 2000), which could result in insensitivity to natural
rewards (anhedonia). This may enhance the tendency of
patients to use the substance of abuse. The psychological
urge to administer a drug is called craving, which is regarded
to be a central phenomenon in substance abuse (Franken,
2003; Robinson and Berridge, 1993). Most ﬁrst generation
antipsychotics have a strong antagonistic eﬀect on dopamine
transmission and could worsen craving and substance abuse
(McEvoy et al., 1995; Siris, 1990). Second generation antipsy-
chotics with a weaker antagonistic eﬀect on dopaminergic
transmission have been found to attenuate craving and
substance abuse (Smelson et al., 2008; Wobrock and Soyka,
2008). Since second generation antipsychotics mutually diﬀer
in their antagonistic eﬀect on dopamine, diﬀerences in eﬀect
on substance abuse and craving between these medications can
be expected. Some studies suggest a superior eﬀect of cloza-
pine in the treatment of co-morbidity of substance use disor-
ders and psychotic disorders (Machielsen and de Haan, 2009;
Smelson et al., 2008;Wobrock and Soyka, 2008). Diﬀerences
between antipsychotic medications in eﬃcacy of treating sub-
stance use disorders (i.e. craving) may be explained by three
possible dopamine mediated mechanisms: 1) diﬀerences in
occupancy rate of dopamine D2 receptors, 2) diﬀerences in
dissociation rate of dopamine D2 receptors, 3) diﬀerences
in D1/D2 ratio (Machielsen and de Haan, 2009). In a study
on occupancy rates of diﬀerent antipsychotics to the dopamine
D2 receptors, Kuroki et al. (2008) found that clozapine had a
low aﬃnity to the dopamine D2 receptor (7.0 pKi) while olan-
zapine had a higher aﬃnity (7.8 pKi) and risperidone had an
aﬃnity to the dopamine D2 receptor (8.9 pKi) comparable to
that of haloperidol (9.0 pKi). Dissociation rates of the diﬀer-
ent antipsychotics were investigated by Seeman (2002). They
found that clozapine showed a fast dissociation of the dopa-
mine D2 receptor, while olanzapine had a medium and risper-
idone and haloperidol had a slow dissociation rate. In a
comparative study on the diﬀerences in ratio of dopamine
D1 and D2 receptor occupancies, Tauscher et al. (2004)
found that the ratio of striatal D1/D2 occupancy was signiﬁ-
cantly higher for clozapine (0.88) relative to olanzapine (0.54),
quetiapine (0.41), or risperidone (0.31).
In the present study, craving for cannabis is compared in
patients using risperidone, olanzapine or clozapine. We chose
tocompare thesemedicationsbecause risperidoneandclozapine
show a maximal diﬀerence in D2 receptor occupancy rate, dis-
sociation rate and D1/D2 ratio. Olanzapine is intermediate
between risperidone and clozapine in these three characteristics.
We intended to test the hypothesis that treatment with
risperidone was associated with more severe craving for can-
nabis compared with treatment with clozapine. We hypothe-
size that levels of craving for cannabis during treatment with
olanzapine would be intermediate between those associated
with risperidone or clozapine.
Methods
Participants
The study sample was taken from 1120 patients who were
examined within the Genetic Risk and Outcome of
Psychosis (GROUP) study. In summary, GROUP is a multi-
site, longitudinal, naturalistic cohort study examining the six-
year course of patients with non-aﬀective psychotic disorders
and their siblings. Patients were recruited from mental health
centres covering more than 75% of the mental health institu-
tions of The Netherlands, including both inpatient and out-
patient clinics. Eligible patients for the GROUP project had
to fulﬁl the following criteria: 1) age between 16 and 50 years,
2) meet Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM IV) (American Psychiatric
Association, 1994) criteria for a non-aﬀective psychotic dis-
order (schizophrenia, schizophreniform disorder, schizoaﬀec-
tive disorder, delusional disorder, psychotic disorder NOS), 3)
ﬂuent in Dutch, and 4) able and willing to give written
informed consent. Persons identiﬁed as potentially eligible
were given a detailed explanation of the study procedures
and were asked for informed consent for assessment. The
study protocol was approved centrally by the Ethical
Review Board of the University Medical Centre Utrecht
and subsequently by local review boards of each participating
institute. After full verbal and written information about the
study, informed consent was obtained from all participants
before the start of the ﬁrst assessment. (For more detailed
information about the GROUP project see Korver et al.,
2012.)
For this study we included patients using risperidone,
olanzapine or clozapine with a diagnosis of cannabis depen-
dence of which data on craving (assessed with the Obsessive
Compulsive Drug Use Scale (OCDUS)) were available. We
excluded patients who used more than one type of antipsy-
chotic medication.
Instruments
Cash/Scan. To establish DSM IV (American Psychiatric
Association, 1994) diagnosis of psychotic disorder, the
Comprehensive Assessment of Symptoms and History
(CASH) (Andreasen et al., 1992) or the SCAN Schedules
for Clinical Assessment for Neuropsychiatry (SCAN 2.1)
(Wing et al., 1990) were used.
CIDI Substance Abuse Module. A special Substance Abuse
Module of the Composite International Diagnostic Interview
(CIDI) (Robins et al., 1988) was used to assess tobacco, alco-
hol, and other drug abuse in considerable detail, allowing the
assessment of the quality and severity of dependence and its
course. This questionnaire was used as a diagnostic tool to
establish DSM IV diagnosis of lifetime cannabis abuse and
dependence. Nicotine use was deﬁned as daily use of ciga-
rettes for at least one month in the past 12 months. Alcohol
use in the past year was deﬁned as having consumed more
than 12 alcoholic drinks in the past 12 months. Illicit sub-
stance use (other than cannabis) in the past year was deﬁned
as having used any hard drug (speed, amphetamines, halluci-
nogens, opiates, cocaine or ecstasy) in the past year.
OCDUS. The Obsessive Compulsive Drug Use Scale
(OCDUS) is a self-rating scale consisting of 12 items with a
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ﬁve-point Likert type rating measuring drug craving in the
past seven days. For this study the OCDUS-CAN was used,
which is a cannabis-speciﬁc version of the OCDUS.
The OCDUS was based on the Obsessive Compulsive
Drinking Scale (OCDS) (Anton et al., 1996), which contains
two underlying factors, namely obsession and compulsions
(Anton et al., 1996). The OCDUS also can be divided
into two comparable factors, namely items 1–6 on thoughts,
and items 7–12 on craving. The OCDUS has been vali-
dated for patients using opiates by Franken et al. (2002).
Recently Dekker et al. (submitted) found evidence supporting
the reliability and validity of the Obsessive Compulsive
Drug Use Scale for cannabis (OCDUS-CAN) in patients
with recent onset non-aﬀective psychotic disorder, their
non-aﬀected siblings, and healthy controls who all used
cannabis in the past year. In a psychometric analysis
three underlying factors (subscales) were found: craving/
urge, resistance and impact. For more details see Dekker
et al. (submitted).
Statistical analysis
Prevalence rates of cannabis dependence in the diﬀerent
medication groups were calculated. To compare the patients
with cannabis dependence with those without cannabis
dependence on demographics and substance use characteris-
tics, chi-square tests and Mann–Whitney U tests were used.
Of the patients with cannabis dependence, demographic and
substance use characteristics were also compared in the dif-
ferent medication groups. Estimations of D2 receptor occu-
pancy rates were made of patients treated with risperidone
or olanzapine using the dose-occupancy function as
described by Lataster et al. (2011). D2 receptor occup-
ancy rates of olanzapine and risperidone were compared
with a t-test.
Because the assumption of normal distribution was violated
for the OCDUS scores, we used the Kruskal–Wallis test to
compare the OCDUS scores of all patients with cannabis
dependence for which OCDUS data were available. We made
comparisons for the OCDUS total score, for the ‘original’ sub-
division of thoughts and craving items and for the more recent
subdivision of craving/urge, resistance and impact as described
before. Post hoc comparisonsweremade usingMann–Whitney
U tests.
Results
Sociodemographic characteristics and prevalence
rates of cannabis dependence
Sample characteristics are shown in Table 1. Our study
population covered 503 patients using risperidone, olanzapine
or clozapine. In the group of patients with cannabis depen-
dence signiﬁcantly more patients were male (n¼ 141; 90.8%
males) compared with the patients without cannabis depen-
dence (n¼ 362; 78.2% males). No diﬀerences were found
in age and ethnicity between these two groups. The abuse
of nicotine, alcohol and other illicit substances was signiﬁ-
cantly higher among patients with cannabis dependence
(Table 1). Of all 503 patients, 187 patients used risperidone,
234 used olanzapine and 82 used clozapine at the time of
the interview, of which, respectively, 54, 60 and 27 patients
were also diagnosed with cannabis dependence. Of these
patients, OCDUS data were available for, respectively, 48, 52
and 23 patients. No diﬀerences were found in age, gender,
ethnicity and the abuse of alcohol or other substances between
the diﬀerent medication groups among the patients with can-
nabis dependence (see Table 2). Of the patients using cloza-
pine, signiﬁcantly fewer patients smoked cigarettes compared
with patients using olanzapine or risperidone (Table 2).
The mean dosage of risperidone was 3.46mg (SD 1.62), of
olanzapine 13.78mg (SD 6.725) and of clozapine 350mg
(SD 166.58) in the group of patients with cannabis dependence.
The mean estimated D2 receptor occupancy according to
Lataster et al. (2011) of risperidone (66.3%) was signiﬁcantly
higher (t¼ 2.18, p¼ .003) compared with olanzapine (61.2%).
OCDUS scores in cannabis-dependent patients
using risperidone, olanzapine or clozapine
Using the Kruskal–Wallis test, signiﬁcant diﬀerences between
the three medication groups were found in OCDUS total
score (Z¼ 5.02, p¼ .005) (see Table 3). In the original subdi-
vision of OCDUS thoughts and craving subscales, signiﬁ-
cant diﬀerences between the medication groups were found
in OCDUS thoughts (Z¼ 4.37, p¼ .017) and craving
(Z¼ 3.93, p¼ .007) items (Table 3). Separate Mann–
Whitney U tests showed signiﬁcant diﬀerences in the




cannabis dependence (n¼ 362) x2 or Z p-value
Gender Male (%) 90.8 78.2 9.959 0.002
Age Mean (SD) 26.5 (5.9) 27.3 (7.7) .331 0.740
Ethnicity Caucasian (%) 74.5 80.3 2.03 0.154
Nicotine use in past year Yes (%) 89.4 57.7 45.6 <0.001
Alcohol use in past year Yes (%) 85.1 68.8 13.7 <0.001
Other illicit substance
use in past yeara
Yes (%) 28.4 8.3 17.0 <0.001
aOther illicit substances: stimulants (speed, amphetamines), hallucinogens, opiates, cocaine, ecstasy.
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OCDUS total score between risperidone and clozapine
(Z¼3.19, p¼ .001) and risperidone and olanzapine
(Z¼2.24, p¼ .025); in the OCDUS thoughts items, between
risperidone and clozapine (Z¼2.73, p¼ .006) and risperi-
done and olanzapine (Z¼2.09, p¼ .036); and in the
OCDUS craving items, between risperidone and clozapine
(Z¼3.16, p¼ .002) and risperidone and olanzapine
(Z¼1.98, p¼ .047). No signiﬁcant diﬀerences were found
between olanzapine and clozapine. All diﬀerences between
risperidone and clozapine were still signiﬁcant after
Bonferroni correction for multiple testing.
In the subscales craving/urge, resistance and impact a sig-
niﬁcant diﬀerence was found between the medications in the
resistance items (Z¼ 18.1, p¼<.001) and trends for diﬀer-
ences were found in craving/urge items and impact items
(Table 3). When the diﬀerent medications were compared
using Mann–Whitney U tests, signiﬁcant diﬀerences were
found in the resistance items between risperidone and olanza-
pine (Z¼3.46, p¼ .001) and risperidone and clozapine
(Z¼3.58, p¼<.001). No signiﬁcant diﬀerences in craving
scores were found between olanzapine and clozapine.
A Mann–Whitney U test revealed no diﬀerence in OCDUS
total scores between male and female patients with cannabis
dependence (Z¼1.09, p¼ .275). A comparison of OCDUS
total score was also made between patients with solitary can-
nabis dependence and patients with both cannabis depen-
dence and abuse of other substances (nicotine, alcohol or
other illicit substances). These comparisons also revealed no
signiﬁcant diﬀerence for nicotine (Z¼1.85, p¼ .065),
alcohol (Z¼.575, p¼ .565) and other illicit substances
(Z¼1.44, p¼ .15).
Discussion
Sociodemographic characteristics and prevalence
rates of cannabis dependence
In the present study population a larger proportion of males
was found among the patients with cannabis dependence
compared with the patients without cannabis dependence.
This is often described in the literature (Cantwell et al.,
1999; Machielsen et al., 2010) and supports the notion that
men have a higher propensity to use substances of abuse.
A higher percentage of patients using cannabis also abused
nicotine, alcohol and other substances. This is in concordance
with the pattern of substance abuse in the general population
and supports the hypothesis that the abuse of diﬀerent sub-
stances has a common cause (Blum et al., 2000).
OCDUS scores in patients using risperidone,
olanzapine or clozapine
We found more severe craving for cannabis in cannabis-
dependent patients treated with risperidone compared with
patients treated with clozapine or olanzapine. This is in con-
cordance with our hypothesis. We are not aware of studies
comparing craving for cannabis in schizophrenia patients
Table 3. OCDUS scores of patients with cannabis dependence using risperidone, olanzapine or clozapine
Risperidone (n¼ 48) Median Olanzapine (n¼ 52) Median Clozapine (n¼ 23) Median Z p-value
OCDUS total 1.83 1.54 1.33 10.7 0.005
Subscales*
Thoughts 1.83 1.67 1.5 8.19 0.017
Craving 1.83 1.50 1.17 10.0 0.007
Subscales**
Craving/urge 2.00 1.60 1.20 5.19 0.075
Resistance 3.00 1.50 1.00 18.1 <0.001
Impact 1.50 1.20 1.20 5.22 0.075
*Subscales according to Anton et al. (1996). **Subscales according to Dekker et al. (submitted)
Table 2. Demographic and substance use characteristics of patients with cannabis dependence
Risperidone (n¼ 48) Olanzapine (n¼ 52) Clozapine (n¼ 23) x2 or Z p-value
Gender Male (%) 89.6 92.3 91.3 0.230 0.892
Age Mean (SD) 26.7 (6.9) 26.8 (5.7) 26.4 (4.0) 0.458 0.795
Ethnicity Caucasian (%) 75.0 80.8 60.9 3.35 0.187
Dosage in mg Mean (SD) 3.46 (1.62) 13.78 (6.73) 350 (166.6)
Nicotine use in past year Yes (%) 93.8 92.3 73.9 7.26 0.003
Alcohol use in past year Yes (%) 87.5 88.5 73.9 3.00 0.224
Other illicit substance use
in past yeara Yes (%) 25.0 36.5 17.4 3.62 0.164
aOther illicit substances: stimulants (speed, amphetamines), hallucinogens, opiates, cocaine, ecstasy.
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using risperidone, clozapine and olanzapine in one study.
However, some studies compared the eﬀect on craving of
two of these medications. van Nimwegen et al. (2008) com-
pared the eﬀect of risperidone and olanzapine on subjective
craving in a double blind randomized controlled trial. They
concluded that there was no diﬀerence in decrease of subjec-
tive craving for cannabis between these two medications. A
limitation of this study was the small proportion of patients
with cannabis abuse (van Nimwegen et al., 2008). In an eight-
week follow up study, Kim et al. (2010) found an increase in
both craving and dependence on nicotine in patients with
schizophrenia treated with risperidone. No change was
found in craving for nicotine in patients using olanzapine.
In a double blind study, Akerele and Levin (2007) found
that patients with schizophrenia and cocaine dependence
who used risperidone reported more craving compared with
patients using olanzapine. Green et al. (2003) showed in a
retrospective assessment of patients with schizophrenia and
cannabis and/or alcohol use disorder that patients treated
with clozapine had a signiﬁcantly higher rate of abstinence
compared with those treated with risperidone.
The better eﬃcacy of clozapine and olanzapine as com-
pared with risperidone in treating substance abuse could be
explained by the lower occupancy rate of the D2 receptor, the
higher dissociation rate of the D2 receptor and the higher D1/
D2 receptor occupancy rate of these medications as compared
with risperidone (Kuroki et al., 2008; Seeman, 2002; Tauscher
et al., 2004). de Haan et al. (2000, 2003) and Mizrahi et al.
(2007) found a signiﬁcant correlation between D2 blockade
and reduced subjective wellbeing of patients with schizophre-
nia. It can be hypothesized that high craving is correlated to
reduced subjective wellbeing. In a former study made by our
group an association was found between number of cigarettes
smoked and a higher occupancy of dopamine D2 receptors in
the ventral striatum in patients using haloperidol, risperidone
or olanzapine (de Haan et al., 2006). In the current study
the D2 receptor occupancy rates of olanzapine and risperi-
done were estimated as described by Lataster et al. (2010).
We found a signiﬁcant diﬀerence in estimated D2 receptor
occupancy between olanzapine and risperidone, although
the absolute mean diﬀerence was not large. We propose
that it is unlikely that the diﬀerence in craving between olan-
zapine and risperidone is exclusively explained by dose depen-
dent diﬀerences in D2 receptor occupancy rate, because the
diﬀerence is not substantial. Olanzapine and risperidone also
diﬀer in dissociation rate and this could be a more likely
explanation for the diﬀerence in craving (Lataster et al.,
2011). However, the diﬀerence in D2 receptor occupancy
rate may partly explain our results. Future studies could com-
pare diﬀerent antipsychotic medication at comparable D2
receptor occupancy. As we mentioned earlier the diﬀerence
in craving could also be based on diﬀerences in D1/D2 recep-
tor occupancy rate. No reliable estimation of D2 receptor
occupancy could be made for clozapine. In the literature no
evidence was found to support a relation between D2 receptor
occupancy and clinical response for clozapine (Pickar et al.,
1996; Seeman, 2002).
Some studies suggest a superior eﬀect of clozapine com-
pared with all other antipsychotics in the treatment of sub-
stance use disorders in patients with dual diagnosis
(Machielsen and de Haan, 2009; Smelson et al., 2008;
Wobrock and Soyka, 2008); however, in the current study
no signiﬁcant diﬀerence in craving was found between olan-
zapine and clozapine.
Some limitations of the current study should be men-
tioned. First, although our ﬁndings are relatively robust and
concur with former ﬁndings, our study was designed as a
naturalistic cross-sectional study, and therefore our ﬁndings
should be interpreted cautiously. A randomized controlled
longitudinal study concerning diﬀerences between second
generation antipsychotics in eﬃcacy on craving and substance
abuse would provide more deﬁnitive answers. Because of the
naturalistic nature of the design a selection bias regarding
antipsychotics cannot be ruled out. Where risperidone and
olanzapine are agents that can be started during the entire
course of treatment, clozapine is an antipsychotic that is indi-
cated for patients who have a treatment refractory illness and
are therefore ill for a longer period of time, usually with a
more severe course of illness. However, since clozapine was
superior to risperidone and equal to olanzapine regarding
eﬃcacy in treatment of substance abuse, it is not likely that
the superior eﬀect on craving is associated with treatment
resistance or illness duration.
Second, a signiﬁcant diﬀerence in gender and abuse of
substances other than cannabis was found between patients
with cannabis dependence and those without cannabis depen-
dence. However, separate analysis to compare craving
between male and female patients within the group of patients
with cannabis dependence revealed no diﬀerences between
these groups. Further, we found no signiﬁcant diﬀerences in
craving between the group of patients with solitary cannabis
dependence and the group of patients with cannabis depen-
dence and abuse of other substances. A third limitation is that
signiﬁcantly fewer patients using clozapine smoked cigarettes
compared with patients using olanzapine or risperidone. This
could interfere with the results since craving for cannabis
could be related to craving for cigarettes. However, no diﬀer-
ences in craving were found between patients with solitary
cannabis dependence and patients with both cannabis depen-
dence and nicotine abuse. The ﬁnding that fewer patients
using clozapine smoked cigarettes may also be important on
its own, since former studies also found that patients using
clozapine tend to smoke less (McEvoy et al., 1999). This could
be explained by diﬀerences in the three dopamine-related fac-
tors we discussed above and is in line with our hypothesis.
Despite above-mentioned limitations, the results of the
current study give support for the hypothesis of diﬀeren-
tial impact of antipsychotic medication (specially between
clozapine and risperidone) on craving for cannabis in patients
with both psychotic disorders and substance use disorders.
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